Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
HCV Advocate

Wednesday, April 18, 2012

INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV

BARCELONA, Spain, April 18, 2012 /PRNewswire via COMTEX/ -- Retrospective sub-analyses from ADVANCE, ILLUMINATE and REALIZE Phase 3 studies will be presented at European Association for the Study of the Liver (EASL) 2012 - 

Janssen Pharmaceutica NV (Janssen) will present new data for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The data shows that similar sustained virologic response (SVR) rates were achieved regardless of ribavirin dose reduction, including dose reduction to = 600mg/day in a telaprevir-based treatment regimen for both treatment naïve and previously treated genotype-1 chronic HCV patients.[1] 

The study abstract is currently published online ( http://www.easl.eu ) and full results will be presented on Saturday 21st April at 12:30pm CET. 

No comments:

Post a Comment